PROMIS NEUROSCIENCES, INC. TORONTO, Ontario and CAMBRIDGE, Mass. - September 11, 2021 - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in H.C. Wainwright & Co., 23rdAnnual Investment Conference being held virtually September 13-15 2021.
ProMIS Executive Chairman, Eugene Williams, will provide an update on the company with special focus on PMN310, ProMIS' lead antibody for Alzheimer's disease (AD), as well as an overview of the Company's unique, proprietary technology platform and ProMIS' expanding portfolio of antibody therapeutic candidates targeting in addition to AD, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and beyond. A narrated version of the slide deck presented at the conference is available on the ProMIS website by clicking on the following link:
https://promisneurosciences.com/news/h-c-wainwright-and-co-23rd-annual-investment-conference/
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
Visit us atwww.promisneurosciences.com, follow us on TwitterandLinkedIn
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
###
- ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment ConferenceSeptember 13, 2021
- ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of DirectorsSeptember 1, 2021
- PROMIS NEUROSCIENCES CLOSES UPSIZED US$20,125,000 PUBLIC OFFERING August 25, 2021
- Podcast Version of Chairman's updateMay 20, 2020
- Introducing Intrabodies with Dr. Johanne Kaplan - PodcastApril 30, 2020
- Worried about aducanumab? Don't be. Dr. Jim Kupiec explains - PodcastApril 28, 2020
- Commentary
- In the News
- News
- Podcasts
- Posters
- Presentations
- Uncategorized
- Video
Attachments
- Original document
- Permalink
Disclaimer
ProMIS Neurosciences Inc. published this content on 13 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 11:11:12 UTC.
